ArticleInfection2023

Early treatment response to piperacillin/tazobactam in patients with bloodstream infections caused by non-ESBL ampicillin/sulbactam-resistant Escherichia coli: a binational cohort study.

Selma Tobudic et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.